NHS to receive £8m from Aspen over anti-competitive practices

Drugmaker Aspen has offered to pay the UK’s National Health System (NHS) £8 million ($9.7 million) to resolve competition concerns.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA

12 March 2020 The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.

Big Pharma

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

9 October 2019 African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.

Big Pharma

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.